These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 27696202)

  • 1. Expression of programmed cell death 1 and programmed cell death ligand 1 in extranodal NK/T-cell lymphoma, nasal type.
    Jo JC; Kim M; Choi Y; Kim HJ; Kim JE; Chae SW; Kim H; Cha HJ
    Ann Hematol; 2017 Jan; 96(1):25-31. PubMed ID: 27696202
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of programmed cell death ligand 1 (PD-L1) in advanced stage EBV-associated extranodal NK/T cell lymphoma is associated with better prognosis.
    Kim WY; Jung HY; Nam SJ; Kim TM; Heo DS; Kim CW; Jeon YK
    Virchows Arch; 2016 Nov; 469(5):581-590. PubMed ID: 27595782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
    Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
    Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Programmed death-ligand 1 and its soluble form are highly expressed in nasal natural killer/T-cell lymphoma: a potential rationale for immunotherapy.
    Nagato T; Ohkuri T; Ohara K; Hirata Y; Kishibe K; Komabayashi Y; Ueda S; Takahara M; Kumai T; Ishibashi K; Kosaka A; Aoki N; Oikawa K; Uno Y; Akiyama N; Sado M; Takei H; Celis E; Harabuchi Y; Kobayashi H
    Cancer Immunol Immunother; 2017 Jul; 66(7):877-890. PubMed ID: 28349165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD30 expression is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type.
    Li P; Jiang L; Zhang X; Liu J; Wang H
    BMC Cancer; 2014 Nov; 14():890. PubMed ID: 25429803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma.
    Paydas S; Bağır E; Seydaoglu G; Ercolak V; Ergin M
    Ann Hematol; 2015 Sep; 94(9):1545-52. PubMed ID: 26004934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD38 expression predicts poor prognosis and might be a potential therapy target in extranodal NK/T cell lymphoma, nasal type.
    Wang L; Wang H; Li PF; Lu Y; Xia ZJ; Huang HQ; Zhang YJ
    Ann Hematol; 2015 Aug; 94(8):1381-8. PubMed ID: 25865943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmed Cell Death 1 and Programmed Cell Death Ligands in Extranodal Natural Killer/T Cell Lymphoma: Expression Pattern and Potential Prognostic Relevance.
    Muhamad H; Suksawai N; Assanasen T; Polprasert C; Bunworasate U; Wudhikarn K
    Acta Haematol; 2020; 143(1):78-88. PubMed ID: 31330525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
    Feng Y; Jing C; Yu X; Cao X; Xu C
    Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
    Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
    Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 is upregulated by EBV-driven LMP1 through NF-κB pathway and correlates with poor prognosis in natural killer/T-cell lymphoma.
    Bi XW; Wang H; Zhang WW; Wang JH; Liu WJ; Xia ZJ; Huang HQ; Jiang WQ; Zhang YJ; Wang L
    J Hematol Oncol; 2016 Oct; 9(1):109. PubMed ID: 27737703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer.
    Calles A; Liao X; Sholl LM; Rodig SJ; Freeman GJ; Butaney M; Lydon C; Dahlberg SE; Hodi FS; Oxnard GR; Jackman DM; Jänne PA
    J Thorac Oncol; 2015 Dec; 10(12):1726-35. PubMed ID: 26473645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of PD-L1 in bladder cancer.
    Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
    Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
    Darb-Esfahani S; Kunze CA; Kulbe H; Sehouli J; Wienert S; Lindner J; Budczies J; Bockmayr M; Dietel M; Denkert C; Braicu I; Jöhrens K
    Oncotarget; 2016 Jan; 7(2):1486-99. PubMed ID: 26625204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous extranodal natural killer/T-cell lymphoma: a comparative clinicohistopathologic and survival outcome analysis of 45 cases according to the primary tumor site.
    Lee WJ; Jung JM; Won CH; Chang SE; Choi JH; Chan Moon K; Park CS; Huh J; Lee MW
    J Am Acad Dermatol; 2014 Jun; 70(6):1002-9. PubMed ID: 24629518
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
    Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
    Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do programmed death 1 (PD-1) and its ligand (PD-L1) play a role in patients with non-clear cell renal cell carcinoma?
    Abbas M; Steffens S; Bellut M; Becker JU; Großhennig A; Eggers H; Wegener G; Kuczyk MA; Kreipe HH; Grünwald V; Schrader AJ; Ivanyi P
    Med Oncol; 2016 Jun; 33(6):59. PubMed ID: 27165272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed Cell Death Ligand 1 Expression in Primary Central Nervous System Lymphomas: A Clinicopathological Study.
    Hayano A; Komohara Y; Takashima Y; Takeya H; Homma J; Fukai J; Iwadate Y; Kajiwara K; Ishizawa S; Hondoh H; Yamanaka R
    Anticancer Res; 2017 Oct; 37(10):5655-5666. PubMed ID: 28982883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.